Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers

Breast Cancer Research and Treatment

Volumn 165, Issue 2, 2017, Pages 247-260

  Lin, Cheryl ^a   Clark, Rachel ^a   Tu, Pikuei ^a   Bosworth, Hayden B ^a,b,c,d   Zullig, Leah L ^b,c,d  

^a DUKE UNIVERSITY   (United States)

^b DURHAM VA HEALTH CARE SYSTEM   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Compliance; Medication adherence; Oral medication; Patient physician relationship; Psychosocial

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; DATA EXTRACTION; DECISION MAKING; DEPRESSION; DISEASE ASSOCIATION; DOCTOR PATIENT RELATION; EMOTION; HEALTH BELIEF; HEALTH CARE COST; HUMAN; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; OBSERVATIONAL STUDY; PATIENT EDUCATION; PERCEPTION DISORDER; PRIORITY JOURNAL; QUALITY CONTROL; RETROSPECTIVE STUDY; REVIEW; SELF CONCEPT; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; SYSTEMATIC REVIEW; BREAST TUMOR; FEMALE; MENTAL STRESS; META ANALYSIS; ORAL DRUG ADMINISTRATION; PSYCHOLOGY; QUALITY OF LIFE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MEDICATION ADHERENCE; PHYSICIAN-PATIENT RELATIONS; QUALITY OF LIFE; STRESS, PSYCHOLOGICAL;

EID: 85020134977     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-017-4317-2     Document Type: Review

References (56)

1. Foulon V, Schoffski P, Wolter P (2011) Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 66(2):85–96
2. Weingart SN et al (2008) NCCN Task Force Report: Oral chemotherapy. J Natl Compr Cancer Netw 6(Suppl 3):S1–S14
3. Fallowfield L et al (2006) Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17(2):205–210
4. Liu G et al (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110–115
5. Mazzoni E et al (2010) 22 Adherence to and persistence with an oral metronomic chemotherapy with capecitabine in heavily pretreated metastatic breast cancer (MBC) patients. Cancer Treat Rev 36:S101
6. Benjamin L et al (2012) Physicians’ preferences for prescribing oral and intravenous anticancer drugs: a discrete choice experiment. Eur J Cancer 48(6):912–920
7. Waterhouse DM et al (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11(6):1189–1197
8. Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59(1):56–66
9. Murphy CC et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478
10. von Mehren M, Widmer N (2011) Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 37(4):291–299
11. Breast cancer statistics. [Web] 2016 March 23, 2016; Available from: https://www.cdc.gov/cancer/breast/statistics/
12. McCowan C et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763–1768
13. Makubate B et al (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515–1524
14. Hershman DL et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537
15. Wood L (2012) A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs 16(4):432–438
16. Partridge AH et al (2002) Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94(9):652–661
17. Culos-Reed SN et al (2000) Predictors of adherence to behavior change interventions in the elderly. Controll Clin Trials 21(5):S200–S205
18. Van Liew JR, Christensen AJ, de Moor JS (2014) Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Cancer Surviv 8(3):521–531
19. Vrijens B et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73(5):691–705
20. Barillet M et al (2015) Oral antineoplastic agents: how do we care about adherence? Br J Clin Pharmacol 80(6):1289–1302
21. Greer JA et al (2016) A systematic review of adherence to oral antineoplastic therapies. Oncologist 21(3):354–376
22. Verbrugghe M et al (2013) Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev 39(6):610–621
23. van Londen GJ et al (2014) Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms. Oncol Nurs Forum 41(6):660–668
24. Rust C, Davis C (2011) Health literacy and medication adherence in underserved African-american breast cancer survivors: a qualitative study. Soc Work Health Care 50(9):739–761
25. Wells KJ et al (2016) Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer 24:4123–4130
26. Neugut AI et al (2016) A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 158:127–138
27. Lebovits AH et al (1990) Patient noncompliance with self-administered chemotherapy. Cancer 65(1):17–22
28. Bhatta SS et al (2013) Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer. Springerplus 2:356
29. Jacob Arriola KR et al (2014) Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns 95(1):98–103
30. Fink AK et al (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor–positive breast cancer. J Clin Oncol 22(16):3309–3315
31. Kirk MC, Hudis CA (2008) Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 8(2):155–161
32. Friese CR et al (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138(3):931–939
33. Lash TL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215–220
34. Hershman DL et al (2016) Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 157(1):133–143
35. Walker HE et al (2016) Perceptions, attributions, and emotions toward endocrine therapy in young women with breast cancer. J Adolesc Young Adult Oncol 5(1):16–23
36. Rust CF, Davis C, Moore MR (2015) Medication adherence skills training for African–American breast cancer survivors: the effects on health literacy, medication adherence, and self-efficacy. Soc Work Health Care 54(1):33–46
37. Manning M, Bettencourt BA (2011) Depression and medication adherence among breast cancer survivors: bridging the gap with the theory of planned behaviour. Psychol Health 26(9):1173–1187
38. Kimmick G et al (2015) Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. Breast 24(5):630–636
39. Liu Y et al (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137(3):829–836
40. Kahn KL et al (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439
41. Llarena NC et al (2015) Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst 107(10):dvj202
42. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2):322–328
43. Bender CM et al (2014) Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum 41(3):274–285
44. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497
45. Malbasa T, Kodish E, Santacroce SJ (2007) Adolescent adherence to oral therapy for leukemia: a focus group study. J Pediatr Oncol Nurs 24(3):139–151
46. Richardson JL et al (1987) Path model of multidimensional compliance with cancer therapy. Health Psychol 6(3):183–207
47. Spoelstra SL et al (2016) Proof of concept of a mobile health short message service text message intervention that promotes adherence to oral anticancer agent medications: a randomized controlled trial. Telemed J E Health 22(6):497–506
48. Tebbi CK et al (1988) The role of parent-adolescent concordance in compliance with cancer chemotherapy. Adolescence 23(91):599–611
49. Stirratt MJ et al (2015) Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med 5(4):470–482
50. Zullig LL et al. (2017) Medication adherence: a practical measurement selection guide using case studies. Patient Education and Couns
51. Blay JY, Rutkowski P (2014) Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. Cancer Treat Rev 40(2):242–247
52. Kondryn HJ et al (2011) Treatment non-adherence in teenage and young adult patients with cancer. Lancet Oncol 12(1):100–108
53. Kanters S et al (2017) Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. Lancet HIV 4(1):e31–e40
54. Viswanathan M et al (2012) Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 157(11):785–795
55. Mathes T et al (2014) Adherence enhancing interventions for oral anticancer agents: a systematic review. Cancer Treat Rev 40(1):102–108
56. Bestvina CM, Zullig LL, Zafar SY (2014) The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. Future Oncol 10(14):2189–2199